DIANTHUS THERAPEUTICS INC (DNTH) Fundamental Analysis & Valuation

NASDAQ:DNTH • US2528281080

Current stock price

87.39 USD
-2.43 (-2.71%)
At close:
87.39 USD
0 (0%)
After Hours:

This DNTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DNTH Profitability Analysis

1.1 Basic Checks

  • DNTH had negative earnings in the past year.
  • In the past year DNTH has reported a negative cash flow from operations.
  • DNTH had negative earnings in each of the past 5 years.
  • In the past 5 years DNTH always reported negative operating cash flow.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of DNTH (-30.58%) is better than 64.53% of its industry peers.
  • DNTH has a Return On Equity of -32.90%. This is in the better half of the industry: DNTH outperforms 73.64% of its industry peers.
Industry RankSector Rank
ROA -30.58%
ROE -32.9%
ROIC N/A
ROA(3y)-25.86%
ROA(5y)-33.44%
ROE(3y)-27.6%
ROE(5y)-39.22%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • DNTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DNTH Health Analysis

2.1 Basic Checks

  • DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DNTH has been increased compared to 1 year ago.
  • The number of shares outstanding for DNTH has been increased compared to 5 years ago.
  • There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 77.07 indicates that DNTH is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of DNTH (77.07) is better than 97.67% of its industry peers.
  • There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 77.07
ROIC/WACCN/A
WACC9.58%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 13.32 indicates that DNTH has no problem at all paying its short term obligations.
  • DNTH has a Current ratio of 13.32. This is amongst the best in the industry. DNTH outperforms 88.37% of its industry peers.
  • A Quick Ratio of 13.32 indicates that DNTH has no problem at all paying its short term obligations.
  • DNTH's Quick ratio of 13.32 is amongst the best of the industry. DNTH outperforms 88.37% of its industry peers.
Industry RankSector Rank
Current Ratio 13.32
Quick Ratio 13.32
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. DNTH Growth Analysis

3.1 Past

  • DNTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -57.69%.
  • The Revenue for DNTH has decreased by -67.35% in the past year. This is quite bad
EPS 1Y (TTM)-57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.54%
Revenue 1Y (TTM)-67.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.08% on average over the next years. This is quite good.
  • Based on estimates for the next years, DNTH will show a very strong growth in Revenue. The Revenue will grow by 194.05% on average per year.
EPS Next Y-10.23%
EPS Next 2Y-11.24%
EPS Next 3Y-10.83%
EPS Next 5Y8.08%
Revenue Next Year-42.5%
Revenue Next 2Y-13.71%
Revenue Next 3Y90.45%
Revenue Next 5Y194.05%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNTH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNTH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • A cheap valuation may be justified as DNTH's earnings are expected to decrease with -10.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.24%
EPS Next 3Y-10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNTH Dividend Analysis

5.1 Amount

  • No dividends for DNTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DNTH Fundamentals: All Metrics, Ratios and Statistics

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (4/24/2026, 8:00:01 PM)

After market: 87.39 0 (0%)

87.39

-2.43 (-2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-07
Inst Owners100.34%
Inst Owner Change-0.03%
Ins Owners0.13%
Ins Owner Change100%
Market Cap4.76B
Revenue(TTM)2.04M
Net Income(TTM)-162.34M
Analysts88.18
Price Target128.3 (46.81%)
Short Float %18.13%
Short Ratio8.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.31%
Min EPS beat(2)-30.33%
Max EPS beat(2)-10.28%
EPS beat(4)2
Avg EPS beat(4)-8.57%
Min EPS beat(4)-30.33%
Max EPS beat(4)5.31%
EPS beat(8)4
Avg EPS beat(8)-7.77%
EPS beat(12)6
Avg EPS beat(12)-44.45%
EPS beat(16)8
Avg EPS beat(16)-34.59%
Revenue beat(2)0
Avg Revenue beat(2)-31.42%
Min Revenue beat(2)-32.64%
Max Revenue beat(2)-30.2%
Revenue beat(4)1
Avg Revenue beat(4)-24.8%
Min Revenue beat(4)-78.11%
Max Revenue beat(4)41.76%
Revenue beat(8)5
Avg Revenue beat(8)86.7%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)67.16%
PT rev (3m)86.58%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)-18.83%
EPS NY rev (1m)-18.08%
EPS NY rev (3m)-22.44%
Revenue NQ rev (1m)-7.14%
Revenue NQ rev (3m)81.62%
Revenue NY rev (1m)-7.08%
Revenue NY rev (3m)-12.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2337.12
P/FCF N/A
P/OCF N/A
P/B 9.64
P/tB 9.64
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-4.52
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.37
OCFYN/A
SpS0.04
BVpS9.06
TBVpS9.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.58%
ROE -32.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.86%
ROA(5y)-33.44%
ROE(3y)-27.6%
ROE(5y)-39.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.89%
Cap/Sales 10.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.32
Quick Ratio 13.32
Altman-Z 77.07
F-Score2
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)155.15%
Cap/Depr(5y)108.78%
Cap/Sales(3y)5.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.54%
EPS Next Y-10.23%
EPS Next 2Y-11.24%
EPS Next 3Y-10.83%
EPS Next 5Y8.08%
Revenue 1Y (TTM)-67.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-71.57%
Revenue Next Year-42.5%
Revenue Next 2Y-13.71%
Revenue Next 3Y90.45%
Revenue Next 5Y194.05%
EBIT growth 1Y-74.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-65.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.08%
OCF growth 3YN/A
OCF growth 5YN/A

DIANTHUS THERAPEUTICS INC / DNTH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DIANTHUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DNTH.


What is the valuation status of DIANTHUS THERAPEUTICS INC (DNTH) stock?

ChartMill assigns a valuation rating of 0 / 10 to DIANTHUS THERAPEUTICS INC (DNTH). This can be considered as Overvalued.


Can you provide the profitability details for DIANTHUS THERAPEUTICS INC?

DIANTHUS THERAPEUTICS INC (DNTH) has a profitability rating of 1 / 10.